Research To Practice | Oncology Videos

Dr. Priyanka Sharma, a leading medical oncologist specializing in breast cancer, shares insights from the ESMO 2025 meeting. She discusses the overall survival benefits of abemaciclib in high-risk localized breast cancer and the long-term efficacy of durvalumab for triple-negative cases. Dr. Sharma also delves into the competitive landscape of treatment choices, examining sacituzumab govitecan's advantages over chemotherapy. Additionally, she highlights patient-reported outcomes, emphasizing that quality of life can be maintained despite certain treatment-induced symptoms.

Dr. Rebecca Shatsky, an academic oncologist specializing in breast cancer, shares insights on biomarker testing for ER-positive metastatic cases. Prof. Francois-Clement Bidard discusses the novel applications of oral SERDs in treatment regimens. Dr. Seth Wander dives into data analyses surrounding oral SERD monotherapy and its integration with ctDNA monitoring. Dr. Hope Rugo emphasizes patient-centered care, reviewing tolerability and management strategies for oral SERDs, ensuring that clinical practices align with patient needs.

Dr. Matthew Lunning is a hematologist specializing in CAR T-cell therapy and bispecific antibodies, while Dr. Sonali M. Smith focuses on lymphoma research and treatment innovations. They discuss the complexities of logistic challenges and early referral strategies for CAR T therapies in high-risk diffuse large B-cell lymphoma (DLBCL). The conversation also highlights the effectiveness of novel agents like epcoritamab and the importance of managing toxicities. They delve into evolving treatment protocols, including the sequence of using bispecifics before CAR T for optimal outcomes.

In this intriguing discussion, Dr. Chris Liu, an expert in colorectal cancer and immunotherapy, shares cutting-edge insights on neoadjuvant immune checkpoint inhibitors and their impressive results in MSI-high rectal cancer. He delves into the significance of recent trials, revealing high clinical response rates. Dr. John Strickler, a specialist in biomarker strategies, explores the role of minimal residual disease and the impact of targeted therapies like BRAF and KRAS. Both guests highlight the evolving landscape of colorectal cancer treatment and the importance of personalized approaches.

In this discussion, Dr. Matthew R Smith, a medical oncologist from Massachusetts General Hospital, and Dr. Emmanuel S Antonarakis from the University of Minnesota, delve into the complexities of prostate cancer treatment. They explore the optimization of hormonal therapy and the potential of emerging therapies like PARP inhibitors and radioligand therapies. The conversation highlights the significance of biomarker testing, practical implications of PSMA PET findings, and the challenges of integrating novel approaches into clinical practice.

Dr Rita Nanda, expert in endocrine-resistant HR+ disease and targeted agents. Dr Harold J. Burstein, HER2 specialist with expertise in neoadjuvant and metastatic strategies. Dr Heather McArthur, authority on triple-negative disease and ADCs. Dr Matthew P. Goetz, investigator in HR+ and CDK4/6 research. They discuss genomic assays, sequencing of CDK4/6 and PI3K/AKT agents, ADC selection and toxicities, HER2 strategies, and ctDNA applications.

In this engaging talk, Dr. Jonathan Strosberg, a leading gastrointestinal oncologist at Moffitt Cancer Center, delves into extrapulmonary neuroendocrine carcinomas (NECs). He explores the classification, grading, and mutational profiles of NECs, highlighting the current treatment paradigms, including the platinum-etoposide approach. Strosberg also discusses the emerging biomarker DLL3 and its potential in targeted therapies, along with innovative immunotherapy strategies and ongoing clinical trials aimed at improving patient outcomes in this challenging area of oncology.

In this engaging conversation, Dr. Jacob Sands, a medical oncologist at Dana-Farber Cancer Institute, dives deep into the exciting world of TROP2-directed antibody-drug conjugates for non-small cell lung cancer. He discusses how to manage adverse events like stomatitis and interstitial lung disease associated with datopotamab deruxtecan. Dr. Sands also highlights the drug's impressive intracranial efficacy and explores the promising role of combining ADCs with immunotherapy, revealing potential breakthroughs in treatment strategies.

Dr Erika Hamilton, a medical oncologist and ADC researcher, offers clinical perspectives on TROP2-directed therapies. She discusses distinct toxicities of different ADCs and practical management tactics. Conversation covers ILD vigilance, mucositis and steroid mouthwash, prolonged antiemetic needs, eye care, PRIMED neutropenia prevention, CNS activity of datopotamab, and challenges in sequencing ADCs.

Featuring perspectives from Dr Natalie S Callander and Dr Sagar Lonial, including the following topics: Introduction (0:00) A Farmer with Myeloma; Is Myeloma the New Chronic Myeloid Leukemia? (2:06) Clinical Trials (12:34) Chimeric Antigen Receptor Therapy (16:11) Bispecific Antibodies (21:38) Antibody-Drug Conjugates; a Patient on Belantamab Mafodotin for 3 Years (30:45) Treatment Options for Relapsed Disease (40:46) Neuropathy (44:43) Alternative Therapies (48:36) 164 Questions (53:20) CME information and select publications